GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » ROE % Adjusted to Book Value

Marksans Pharma (NSE:MARKSANS) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma ROE % Adjusted to Book Value?

Marksans Pharma's ROE % for the quarter that ended in Dec. 2023 was 17.75%. Marksans Pharma's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Marksans Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.


Marksans Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Marksans Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma ROE % Adjusted to Book Value Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.45 23.02 13.56 11.40 10.04

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.43 - 6.80 -

Competitive Comparison of Marksans Pharma's ROE % Adjusted to Book Value

For the Drug Manufacturers - General subindustry, Marksans Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's ROE % Adjusted to Book Value falls into.



Marksans Pharma ROE % Adjusted to Book Value Calculation

Marksans Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=18.07% / 1.80
=10.04%

Marksans Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=17.75% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines